Nintedanib in the treatment of idiopathic pulmonary fibrosis

Therapeutic Advances in Respiratory Disease

Volumn 9, Issue 3, 2015, Pages 121-129

  Mazzei, Mariano E ^a   Richeldi, Luca ^b   Collard, Harold R ^c  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

disease progression; forced vital capacity; interstitial lung disease; safety; treatment outcome; tyrosine kinase

Indexed keywords

NINTEDANIB; PIRFENIDONE; PLACEBO; ENZYME INHIBITOR; INDOLE DERIVATIVE; PROTEIN TYROSINE KINASE;

ABDOMINAL PAIN; ASTHENIA; BINDING AFFINITY; BINDING SITE; BRONCHITIS; CLINICAL EFFECTIVENESS; COUGHING; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; HYPERTRANSAMINASEMIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; TREATMENT DURATION; VOMITING; ADULT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; IDIOPATHIC PULMONARY FIBROSIS; PATIENT SELECTION;

ADULT; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; PATIENT SELECTION; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84930694331     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465815579365     Document Type: Review

References (32)

1. Ahluwalia N. Shea B. Tager A. (2014) New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound healing responses. Am J Respir Crit Care Med 190: 867–878.
2. Boehringer Ingelheim Pharmaceuticals, Inc. (2014) OFEV™ (nintedanib) prescribing information. Ridgefield, CT. Available at: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Ofev/ofev.pdf ( accessed 30 October 2014).
3. Boehringer Ingelheim Pharmaceuticals, Inc. (2015) OFEV (nintedanib). Summary of product characteristics. Boehringer Ingelheim Pharmaceuticals, Inc., RE Available at: http://www.ema.europa.eu/ema ( accessed 20 March 2015).
4. Collard H. Moore B. Flaherty K. Brown K. Kaner R. King T. Jr. (2007) Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176: 636–643.
5. Costabel U. Richeldi L. Azuma A. Inoue Y. Collard H. Tschoepe I. (2014) Pre-specified subgroup analyses of pooled data from the INPULSIS™ trials of nintedanib in idiopathic pulmonary fibrosis. The International Colloquium on Lung and Airway Fibrosis, Mont Tremblant, Canada, 20–24 September 2014. Available at: http://www.iclaf.com/conference/index.php/2014/ICLAF/paper/view/106 ( accessed 3 November 2014).
6. Cottin V. Taniguchi H. Richeldi L. Collard H. Kaye M. Hansell D. (2014) Effect of baseline emphysema on reduction in FVC decline with nintedanib in the INPULSIS™ trials. The International Colloquium on Lung and Airway Fibrosis, Mont Tremblant, Canada, 20–24 September 2014. Available at: http://www.iclaf.com/conference/index.php/2014/ICLAF/paper/view/151 ( accessed 3 November 2014).
7. Fernandez I. Eickelberg O. (2012) New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet 380: 680–688.
8. Fingerlin T. Murphy E. Zhang W. Peljto A. Brown K. Steele M. (2013) Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 45: 613–620.
9. Garcia C. (2011) Idiopathic pulmonary fibrosis: update on genetic discoveries. Proc Am Thorac Soc 8: 158–162.
10. Hilberg F. Roth G. Krssak M. Kautschitsch S. Sommergruber W. Tontsch-Grunt U. (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68: 4774–4782.
11. Hostettler K. Zhong J. Papakonstantinou E. Karakiulakis G. Tamm M. Seidel P. (2014) Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res 15: 157.
12. InterMune, Inc. (2014) ESBRIET® (pirfenidone) prescribing information. InterMune, Inc., Brisbane, CA. Available at: www.esbriet.com ( accessed 3 November 2014).
13. Kishaba T. Tamaki H. Shimaoka Y. Fukuyama H. Yamashiro S. (2014) Staging of acute exacerbation in patients with idiopathic pulmonary fibrosis. Lung 192: 141–149.
14. Kolb M. Inoue Y. Costabel U. Hernandez P. Bailes Z. Schlenker-Herceg R. (2014) Effect of FEV1/FVC ratio on reduction in FVC decline with nintedanib in the INPULSIS™ trials. The International Colloquium on Lung and Airway Fibrosis, Mont Tremblant, Canada, 20–24 September 2014. Available at: http://www.iclaf.com/conference/index.php/2014/ICLAF/paper/view/149 ( accessed 3 November 2014).
15. Lee J. McLaughlin S. Collard H. (2011) Comprehensive care of the patient with idiopathic pulmonary fibrosis. Curr Opin Pulm Med 17: 348–354.
16. Ley B. Collard H. (2013) Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol 5: 483–492.
17. Ley B. Collard H. King T. Jr (2011) Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183: 431–440.
18. Natsuizaka M. Chiba H. Kuronuma K. Otsuka M. Kudo K. Mori M. (2014) Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med 190: 773–779.
19. Ogura T. Taniguchi H. Azuma A. Inoue Y. Kondoh Y. Hasegawa Y. (2014). Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 10 December (epub ahead of print).
20. Raghu G. Chen S. Yeh W. Maroni B. Li Q. Lee Y. (2014) Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11. Lancet Respir Med 2: 566–572.
21. Raghu G. Collard H. Egan J. Martinez F. Behr J. Brown K. (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183: 788–824.
22. Richeldi L. Costabel U. Selman M. Kim D. Hansell D. Nicholson A. (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365: 1079–1087.
23. Richeldi L. Cottin V. Flaherty K. Kolb M. Inoue Y. Raghu G. (2014a) Design of the INPULSIS trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir Med 108: 1023–1030.
24. Richeldi L. du Bois R. Raghu G. Azuma A. Brown K. Costabel U. (2014b) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370: 2071–2082.
25. Richeldi L. Kirsten A. Roman J. Le Maulf F. Hallmann C. Stowasser S. (2014c) Pooled analysis of mortality data from the TOMORROW and INPULSIS™ trials of nintedanib in idiopathic pulmonary fibrosis (IPF). The International Colloquium on Lung and Airway Fibrosis, Mont Tremblant, Canada, 20–24 September 2014. Available at: http://www.iclaf.com/conference/index.php/2014/ICLAF/paper/view/202 ( accessed 3 November 2014).
26. Ryerson C. Collard H. (2014) Acute exacerbations complicating interstitial lung disease. Curr Opin Pulm Med 20: 436–441.
27. Song J. Hong S. Lim C. Koh Y. Kim D. (2011) Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 37: 356–363.
28. Stopfer P. Rathgen K. Bischoff D. Lüdtke S. Marzin K. Kaiser R. (2011) Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica 41: 297–311.
29. Wollin L. Maillet I. Quesniaux V. Holweg A. Ryffel B. (2014) Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 349: 209–220.
30. Wollin L. Wex E. Pautsch A. Schnapp G. Hostettler K. Stowasser S. (2015) Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 5 March (epub ahead of print).
31. Wolters P. Collard H. Jones K. (2014) Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol 9: 157–179.
32. Wuyts W. Antoniou K. Borensztajn K. Costabel U. Cottin V Crestani B. (2014) Combination therapy: the future of management for idiopathic pulmonary fibrosis? Lancet Respir Med 2: 933–942.